Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
August 14, 2024 16:01 ET
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 13, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 13, 2024 07:35 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 13, 2024 07:10 ET
|
atai Life Sciences
atai Reports Q2 2024 Financial Results and Corporate Updates
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024 07:00 ET
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
August 09, 2024 16:20 ET
|
Edesa Biotech, Inc.
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 08, 2024 19:20 ET
|
HilleVax, Inc.
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine...
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 08:00 ET
|
Phathom Pharmaceuticals
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second...
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
August 08, 2024 08:00 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights